Lupin Limited has successfully launched Sugammadex Injection in the United States following approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA). According to the company's official announcement, the launch covers Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vial formulations. This marks a significant milestone for the global pharmaceutical leader as it expands its U.S. market presence with this specialized injection product.
The approved Sugammadex Injection is bioequivalent to Bridion® Injection of Merck, Sharp & Dohme LLC (Merck) and is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery. As reported by Lupin, this product represents a specialized therapeutic solution for patients undergoing surgical procedures requiring neuromuscular blockade reversal. The injection is manufactured under strict regulatory standards to ensure bioequivalence to the reference listed drug.
According to IQVIA MAT May 2026 data cited by Business Standard, Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), Single-Dose Prefilled Syringes had an estimated annual sales of USD 77.9 million in the U.S. market. This substantial market opportunity represents a significant revenue potential for Lupin in the American pharmaceutical market, as confirmed by the company's official announcement. The launch of Sugammadex Injection further strengthens Lupin's position in the U.S. market across multiple therapeutic areas.
Lupin shares experienced a decline of 2.17% to ₹2,357.70 in early trade on Wednesday, despite the company's recent corporate announcements including the U.S. FDA approval and launch of Sugammadex Injection. According to market analysis, the pharmaceutical major remains a constituent of the Nifty Midcap 150 index, indicating its standing in the broader market. Market sentiment for Lupin is currently very bullish as of July 29, 2026, suggesting this dip could be a temporary fluctuation rather than a reflection of the company's fundamentals.
